Responsible research and innovation features the dialog of science “with society,” and research performed “for society,” i.e., for the benefit of the people. I focus on this latter, outcome-oriented notion of RRI and discuss two kinds of problems. The first one concerns options to anticipate the future course of science and technology. Such foresight knowledge seems necessary for subjecting research to demands of social and moral responsibility. However, predicting science and technology is widely considered impossible. The second problem concerns moral (...) evaluation. The benefit or harm produced by certain research and innovation achievements is often hard to estimate. Against this background of uncertainty in factual and moral assessment, I explore opportunities left for RRI. First, RRI should contribute to maintaining a wide range of approaches. Second, judgments about RRI should draw on zones of convergence among the variety of research approaches pursued. Third, decisions about implementing a technology should be revisable. Fourth, the more specific inclusion of demands from society should be reserved to technology development. Fifth, in many respects, the social compatibility of a new technology is due rather to the social context than the inherent features of the product. Favorable circumstances are transparency, representation of all relevant parties, and procedural fairness. As a result, some of the benefits and detriments of research and innovation can be identified without detailed knowledge of future findings. (shrink)

In psychiatry, pharmacological research has played a crucial role in the formulation, revision, and refinement of neurobiological theories of psychopathology. Besides being utilized as potential treatments for various mental disorders, pharmacological drugs play an important epistemic role as experimental instruments that help scientists uncover the neurobiological underpinnings of mental disorders (Tsou, 2012). Interventions with psychiatric patients using pharmacological drugs provide researchers with information about the neurobiological causes of mental disorders that cannot be obtained in other ways. This important source of (...) evidence for the biological causes of mental disorder is often overlooked in philosophical analyses of psychiatry, especially in skeptical analyses that debase the biological aspects of psychopathology (e.g., Szasz, 1960; Scheff, 1963; Laing, 1967). In discussing pharmacological interventions as a form of evidence for the physical basis of mental disorders, this paper aims to clarify the nature, reliability, and limitations of this evidence. In addition, it illustrates the central role that pharmacological findings in applied clinical contexts play in the acquisition of neurobiological knowledge in research contexts. (shrink)